Comparison of Inhibitory Effects between Enalapril and Losartan on Adrenal Catecholamine Secretion

키워드

참고문헌 (60)

1. Douglas WW, "Stimulation of uptake of calcium-45 in the adrenal gland by acetylcholine", Nature, 192, pp.1299~ (1961)
2. Wilson SP, "The acetylcholine receptor of the adrenal medulla", J Neurochem, 28, pp.687~695 (1977)
3. Holz RW, "Relationship between Ca2+uptake and catecholamine secretion in primary dissociated cultures of adrenal medulla", J Neurochem, 39, pp.635~646 (1982)
4. Gavras I, "The renin-angiotensin system", pp.40~ (1993), Gower Medical Publishing
5. Nap A, "AT(1)-receptor blockade and sympathetic neurotransmission in cardiovascular disease", Auton Autacoid Pharmacol, 23, pp.285~296 (2003)
6. Feldberg W, "The action of peptides on the adrenal medulla : release of adrenaline by bradykinin and angiotensin", J Physiol, 171, pp.98~108 (1964)
7. Chulak C, "Modulatory effect of bradykinin on the release of noradrenaline from rat isolated atria", Br J Pharmacol, 115, pp.330~334 (1995)
8. Rump LC, "Angiotensin converting enzyme inhibition unmasks the sympathofacilitatory effect of bradykinin in human right atrium", J Hypertens, 15, pp.1263~1270 (1997)
9. Starke K, "Bradykinin and postganglionic sympathetic transmission", Naunyn Schmiedebergs Arch Pharmacol, 299, pp.23~32 (1977)
10. Franchi F, "Cardiac autonomic tone during trandolapril-irbesartan low-dose combined therapy in hypertension : a pilot project", J Hum Hypertens, 16, pp.597~604 (2002)
11. Karas M, "Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients", J Hypertens, 23, pp.1251~1260 (2005)
12. Sakata K, "Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension", J Hypertens, 20, pp.103~110 (2002)
13. Balt JC, "Inhibition of angiotensin II-induced facilitation of sympathetic neurotransmission in the pithed rat : a comparison between losartan, irbesartan, telmisartan, and captopril", J Hypertens, 19, pp.465~473 (2001)
14. Randa HD, "Goodman and Gilman’s the pharmacological basis of therapeutics", pp.721~744 (2011), McGraw-Hill, Health Publishing Division
15. Ball SG, "Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine", Am J Cardiol, 91(10A), pp.15G~21G (2003)
16. Wakade AR., "Studies on secretion of catecholamines evoked by acetylcholine or transmural stimulation of the rat adrenal gland", J Physiol, 313, pp.463~480 (1981)
17. Anton AH, "A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines", J Pharmacol Exp Ther, 138, pp.360~375 (1962)
18. Tallarida RJ, "Manual of pharmacologic calculation with computer programs", pp.110~120 (1987), Springer-Verlag
19. Hammer R, "Muscarinic receptor subtypes : M1and M2 biochemical and functional characterization", Life Sci, 31, pp.2991~2998 (1982)
20. Hano T, "Angiotensin II subtype 1 receptor modulates epinephrine release from isolated rat adrenal gland", Blood Press Suppl, 5, pp.105~108 (1994)
21. Garcia AG, "Dihydropyridine BAY-K-8644 activates chromaffin cell calcium channels", Nature, 309, pp.69~71 (1984)
22. Lim DY, "Influence of TMB-8 on secretion of catecholamines from the perfused rat adrenal glands", Arch Pharm Res, 15, pp.115~125 (1992)
23. Goeger DE, "Interaction of cyclopiazonic acid with rat skeletal muscle sarcoplasmic reticulum vesicles. Effect on Ca2+ binding and Ca2+ permeability", Biochem Pharmacol, 38, pp.3995~4003 (1989)
24. Seidler NW, "Cyclopiazonic acid is a specific inhibitor of the Ca2+-ATPase of sarcoplasmic reticulum", J Biol Chem, 264, pp.17816~17823 (1989)
25. Wada Y, "Cardiovascular profile of Bay K 8644, a presumed calcium channel activator, in the dog", Naunyn Schmiedebergs Arch Pharmacol, 328, pp.382~387 (1985)
26. Martineau D, "Inhibition by BMS 186295, a selective nonpeptide AT1 antagonist, of adrenal catecholamine release induced by angiotensin II in the dog in vivo", Can J Physiol Pharmacol, 73, pp.459~464 (1995)
27. Martineau D, "Functional evidence for L-type Ca2+ channels controlling ANG II-induced adrenal catecholamine release in vivo", Am J Physiol, 271(6Pt 2), pp.R1713~R1719 (1996)
28. Martineau D, "Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo", Can J Physiol Pharmacol, 77, pp.367~374 (1999)
29. Yamaguchi N, "Functional role of local angiotensin-converting enzyme(ACE)in adrenal catecholamine secretion in vivo", Can J Physiol Pharmacol, 77, pp.878~885 (1999)
30. Cavadas C, "Angiotensin II mediates catecholamine and neuropeptide Y secretion in human adrenal chromaffin cells through the AT1 receptor", Regul Pept, 111, pp.61~65 (2003)
31. Critchley L, "The effects of candesartan and ramipril on adrenal catecholamine release in anaesthetized dogs", Eur J Pharmacol, 489, pp.67~75 (2004)
32. Koji T, "Addition of angiotensin II receptor antagonist to an ACE inhibitor in heart failure improves cardiovascular function by a bradykinin-mediated mechanism", J Cardiovasc Pharmacol, 41, pp.632~639 (2003)
33. Akat PB, "Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension", Indian J Pharmacol, 42, pp.153~156 (2010)
34. Zou Z, "Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension : a meta-analysis of randomized controlled trials", J Hum Hypertens, 23, pp.339~349 (2009)
35. Lewandowski J, "The effect of enalapril and telmisartan on clinical and biochemical indices of sympathetic activity in hypertensive patients", Clin Exp Hypertens, 30, pp.423~432 (2008)
36. Smith DH., "Treatment of hypertension with an angiotensin II-receptor antagonist compared with an angiotensin-converting enzyme inhibitor : a review of clinical studies of telmisartan and enalapril", Clin Ther, 24, pp.1484~1501 (2002)
37. Schramm M, "Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels", Nature, 303, pp.535~537 (1983)
38. Fisher SK, "Muscarinic receptors in chromaffin cell cultures mediate enhanced phospholipid labeling but not catecholamine secretion", J Neurochem, 37, pp.491~497 (1981)
39. Yanagihara N, "Muscarinic receptor-mediated increase in cyclic GMP level in isolated bovine adrenal medullary cells", FEBS Lett, 105, pp.296~298 (1979)
40. Wakade AR, "Contribution of nicotinic and muscarinic receptors in the secretion of catecholamines evoked by endogenous and exogenous acetylcholine", Neuroscience, 10, pp.973~978 (1983)
41. Lim DY, "Studies on secretion of catecholamines evoked by DMPP and McN-A-343 in the rat adrenal gland", Korean J Pharmacol, 27, pp.53~67 (1991)
42. Kilpatrick DL, "Calcium uptake and catecholamine secretion by cultured bovine adrenal medulla cells", J Neurochem, 38, pp.427~435 (1982)
43. Kilpatrick DL, "Calcium uptake and catecholamine secretion by cultured bovine adrenal medulla cells", J Neurochem, 38, pp.427~435 (1982)
44. Knight DE, "Evoked transient intracellular free Ca2+ changes and secretion in isolated bovine adrenal medullary cells", Proc R Soc Lond B Biol Sci, 218, pp.177~199 (1983)
45. Wada A, "Influx of 22Na through acetylcholine receptor-associated Na channels : relationship between 22Na influx, 45Ca influx and secretion of catecholamines in cultured bovine adrenal medulla cells", Neuroscience, 15, pp.283~292 (1985)
46. Kidokoro Y, "Chromaffin cell action potentials and their possible role in adrenaline secretion from rat adrenal medulla", J Physiol, 307, pp.199~216 (1980)
47. Burgoyne RD., "Mechanisms of secretion from adrenal chromaffin cells", Biochim Biophys Acta, 779, pp.201~216 (1984)
48. Oka M, "Catecholamines: basic and clinical frontiers", pp.70~72 (1979), Pergamon Press
49. Suzuki M, "Cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca(2+)-pump, reduces Ca(2+)-dependent K+ currents in guinea-pig smooth muscle cells", Br J Pharmacol, 107, pp.134~140 (1992)
50. Iino M., "Calcium-induced calcium release mechanism in guinea pig taenia caeci", J Gen Physiol, 94, pp.363~383 (1989)
51. Uyama Y, "Effects of cyclopiazonic acid, a novel Ca(2+)-ATPase inhibitor, on contractile responses in skinned ileal smooth muscle", Br J Pharmacol, 106, pp.208~214 (1992)
52. Cheek TR, "Spatial localization of the stimulus-induced rise in cytosolic Ca2+ in bovine adrenal chromaffin cells : distinct nicotinic and muscarinic patterns", FEBS Lett, 247, pp.429~434 (1989)
53. Challis RA, "Changes in inositol 1, 4, 5-trisphosphate and inositol 1, 3, 4, 5-tetrakisphosphate mass accumulations in cultured adrenal chromaffin cells in response to bradykinin and histamine", J Neurochem, 56, pp.1083~1086 (1991)
54. Azizi M, "Additive effects of losartan and enalapril on blood pressure and plasma active renin", Hypertension, 29, pp.634~640 (1997)
55. Raasch W, "Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR", J Hypertens, 22, pp.611~618 (2004)
56. Klingbeil AU, "A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension", Am J Med, 115, pp.41~46 (2003)
57. Brilla CG, "Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease", Circulation, 102, pp.1388~1393 (2000)
58. Diez J, "Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients", Circulation, 105, pp.2512~2517 (2002)
59. Devereux RB, "Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol : the Losartan Intervention for Endpoint Reduction in Hypertension(LIFE)trial", Circulation, 110, pp.1456~1462 (2004)
60. Suzuki H, "Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy", Ther Apher Dial, 8, pp.320~327 (2004)

관련 논문AI추천